ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

AbbVie and Boehringer Ingelheim side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

AbbVieBoehringer Ingelheim
studies on the registry2,2512,305
open to participants now13361
phase 3 studies under way7428
reach primary completion within a year9045
programswith a study of their own in two years70+8 named only45+21 named only

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseAbbVieBoehringer Ingelheim
Phase 1

AbbVie: 28 of its 70 programs at phase 1

  1. Anti-CD19-Glucosteroid Receptor Modulator ADC ABBV-31phase 1
  2. surzetoclaxphase 1
  3. BTK Degrader ABBV-101phase 1
  4. ABBV-1162phase 1
  5. ABBV-1451phase 1

and 23 more — sign in to see them all

40%

Boehringer Ingelheim: 18 of its 45 programs at phase 1

  1. BI 3821001phase 1
  2. BI 3000202_low dosephase 1
  3. BI 3776528phase 1
  4. BI 3810944phase 1
  5. BI 3814916phase 1

and 13 more — sign in to see them all

40%
Phase 2

AbbVie: 20 of its 70 programs at phase 2

  1. ABBV-295phase 2
  2. zumilokibartphase 2
  3. ABBV-932phase 2
  4. trosunilimabphase 2
  5. ABBV-701phase 2

and 15 more — sign in to see them all

29%

Boehringer Ingelheim: 15 of its 45 programs at phase 2

  1. BI 3034701phase 2
  2. Anti-SIRPa Monoclonal Antibody BI 770371phase 2
  3. BI 1584862phase 2
  4. BI 1815368phase 2
  5. BI 3000202phase 2

and 10 more — sign in to see them all

33%
Phase 3

AbbVie: 16 of its 70 programs at phase 3

  1. telisotuzumab adizutecanphase 3
  2. etentamigphase 3
  3. lutikizumabphase 3
  4. mirvetuximab soravtansinephase 3
  5. turmetabart adizutecanphase 3

and 11 more — sign in to see them all

23%

Boehringer Ingelheim: 9 of its 45 programs at phase 3

  1. obrixtamigphase 3
  2. survodutidephase 3
  3. nerandomilastphase 3
  4. verducatibphase 3
  5. zongertinibphase 3

and 4 more — sign in to see them all

20%
Approved, new studies

AbbVie: 6 of its 70 programs at approved, new studies

  1. upadacitinibapproved, new study
  2. risankizumabapproved, new study
  3. venetoclaxapproved, new study
  4. botulinum toxin type Aapproved, new study
  5. atogepantapproved, new study

and 1 more — sign in to see them all

9%

Boehringer Ingelheim: 3 of its 45 programs at approved, new studies

  1. empagliflozinapproved, new study
  2. Tenecteplaseapproved, new study
  3. Pramipexoleapproved, new study
7%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
AbbVie34 readouts · 5 phase 3

AbbVie, Nov ’26: 6 programs whose next study reaches primary completion, 1 in phase 3

  1. ABBV-701phase 2 · Nov 0 · NCT06895343
  2. ABBV-932phase 2 · Nov 0 · NCT06846320
  3. mirvetuximab soravtansinephase 3 · Nov 0 · NCT05456685
  4. upadacitinibapproved, new study · Nov 0 · NCT06389136
  5. venetoclaxapproved, new study · Nov 0 · NCT04895436

and 1 more — sign in to see them all

AbbVie, Dec ’26: 4 programs whose next study reaches primary completion, 1 in phase 3

  1. ABBV-295phase 2 · Dec 0 · NCT07514260
  2. emraclidinephase 2 · Dec 0 · NCT07219030
  3. lutikizumabphase 3 · Dec 0 · NCT06468228
  4. telisotuzumab adizutecanphase 3 · Dec 0 · NCT06107413

AbbVie, Jan ’27: 1 program whose next study reaches primary completion

  1. risankizumabapproved, new study · Jan 0 · NCT07466550

AbbVie, Feb ’27: 9 programs whose next study reaches primary completion

  1. [11C]ABBV-112iearly phase 1 · Feb 0 · NCT07933497
  2. ABBV-859phase 1 · Feb 0 · NCT07736638
  3. Anti-CD19-Glucosteroid Receptor Modulator ADC ABBV-31phase 1 · Feb 0 · NCT05512390
  4. etentamigphase 3 · Feb 0 · NCT06223516
  5. MEDI0618phase 2 · Feb 0 · NCT06602479

and 4 more — sign in to see them all

·

AbbVie, Apr ’27: 1 program whose next study reaches primary completion

  1. ABBV-1451phase 1 · Apr 0 · NCT07570147

AbbVie, May ’27: 6 programs whose next study reaches primary completion, 1 in phase 3

  1. ABBV-1162phase 1 · May 0 · NCT07832708
  2. ABBV-243phase 1 · May 0 · NCT07306754
  3. ABBV-7828phase 1 · May 0 · NCT07856706
  4. Anti-PSMA/STEAP1 Antibody-drug Conjugate ABBV-969phase 1 · May 0 · NCT06318273
  5. trosunilimabphase 2 · May 0 · NCT07925983

and 1 more — sign in to see them all

AbbVie, Jun ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. botulinum toxin type Aapproved, new study · Jun 0 · NCT07794891

AbbVie, Jul ’27: 4 programs whose next study reaches primary completion

  1. ABBV-1606phase 1 · Jul 0 · NCT07935564
  2. azirkitugphase 1 · Jul 0 · NCT05005403
  3. surzetoclaxphase 2 · Jul 0 · NCT06291220
  4. surzetoclaxphase 1 · Jul 0 · NCT06291220

AbbVie, Aug ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. vedolizumabphase 3 · Aug 0 · NCT06880744

AbbVie, Sep ’27: 1 program whose next study reaches primary completion

  1. icalcaprantphase 2 · Sep 0 · NCT07276997
·
Boehringer Ingelheim20 readouts · 3 phase 3·

Boehringer Ingelheim, Dec ’26: 8 programs whose next study reaches primary completion, 1 in phase 3

  1. survodutidephase 3 · Dec 8 · NCT07768813
  2. zongertinibphase 3 · Dec 10 · NCT06151574
  3. empagliflozinapproved, new study · Dec 11 · NCT07845630
  4. vicadrostatphase 3 · Dec 11 · NCT07845630
  5. verducatibphase 3 · Dec 14 · NCT07781631

and 3 more — sign in to see them all

·

Boehringer Ingelheim, Feb ’27: 1 program whose next study reaches primary completion

  1. BI 3776528phase 1 · Feb 3 · NCT06745297

Boehringer Ingelheim, Mar ’27: 4 programs whose next study reaches primary completion

  1. BI 764524phase 2 · Mar 5 · NCT06321302
  2. ezabenlimabphase 3 · Mar 8 · NCT05846516
  3. BI 765423phase 2 · Mar 11 · NCT07036523
  4. BI 3812465phase 2 · Mar 23 · NCT07553429

Boehringer Ingelheim, Apr ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. nerandomilastphase 3 · Apr 15 · NCT06806592
·

Boehringer Ingelheim, Jun ’27: 1 program whose next study reaches primary completion

  1. BI 3821001phase 1 · Jun 22 · NCT07908004

Boehringer Ingelheim, Jul ’27: 2 programs whose next study reaches primary completion

  1. BI 3814916phase 1 · Jul 12 · NCT07486115
  2. BI 3032950phase 2 · Jul 30 · NCT06636656

Boehringer Ingelheim, Aug ’27: 2 programs whose next study reaches primary completion

  1. BI 3802876phase 2 · Aug 5 · NCT07325526
  2. Anti-SIRPa Monoclonal Antibody BI 770371phase 2 · Aug 31 · NCT06806852
·

Boehringer Ingelheim, Oct ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. Tenecteplaseapproved, new study · Oct 2 · NCT07361302
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 22, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

AbbVie

New programs 5

Reached a new phase 1

  • ABBV-722phase 3 · Oct 23 · Scleroderma, Systemic

Study stopped 0

None

Primary completion later 10

Boehringer Ingelheim

New programs 3

  • BI 4015092phase 1 · first study · Nov 3
  • BI 3968621phase 1 · first study · Sep 25
  • pumitamigphase 2 · first study · Sep 22 · Carcinoma, Non-Small-Cell Lung

Reached a new phase 1

  • BI 3810477phase 2 · Nov 3 · Idiopathic Pulmonary Fibrosis

Study stopped 0

None

Primary completion later 7

Where they overlap

Conditions where at least two of them have programs: 22 in all. A program counts in each condition its studies name most.

ConditionAbbVieBoehringer Ingelheim
Carcinoma, Non-Small-Cell Lungboth · compare here

AbbVie in Carcinoma, Non-Small-Cell Lung: 4 programs

  1. telisotuzumab adizutecanphase 3
  2. ABBV-1480phase 3
  3. azirkitugphase 1
  4. RC148no phase

Their studies: AbbVie’s studies of Carcinoma, Non-Small-Cell Lung in search

Boehringer Ingelheim in Carcinoma, Non-Small-Cell Lung: 4 programs

  1. zongertinibphase 3
  2. ezabenlimabphase 3
  3. Etoposidephase 3
  4. pumitamigphase 2

Their studies: Boehringer Ingelheim’s studies of Carcinoma, Non-Small-Cell Lung in search

Small Cell Lung Carcinomaboth · compare here

Boehringer Ingelheim in Small Cell Lung Carcinoma: 5 programs

  1. obrixtamigphase 3
  2. ezabenlimabphase 3
  3. Etoposidephase 3
  4. pumitamigphase 2
  5. Zocilurtatug Pelitecanphase 2

Their studies: Boehringer Ingelheim’s studies of Small Cell Lung Carcinoma in search

Colorectal Neoplasmsboth · compare here

AbbVie in Colorectal Neoplasms: 3 programs

  1. telisotuzumab adizutecanphase 3
  2. trifluridine tipiracil drug combinationphase 3
  3. RC148no phase

Their studies: AbbVie’s studies of Colorectal Neoplasms in search

Boehringer Ingelheim in Colorectal Neoplasms: 3 programs

  1. ezabenlimabphase 3
  2. pumitamigphase 2
  3. Anti-B7-H6/Anti-CD3 Bispecific Antibody BI 765049phase 1

Their studies: Boehringer Ingelheim’s studies of Colorectal Neoplasms in search

Colitis, Ulcerativeboth · compare here

AbbVie in Colitis, Ulcerative: 4 programs

  1. vedolizumabphase 3
  2. ravagalimabphase 2
  3. upadacitinibapproved, new study
  4. risankizumabapproved, new study

Their studies: AbbVie’s studies of Colitis, Ulcerative in search

Boehringer Ingelheim in Colitis, Ulcerative: 1 program

  1. BI 3032950phase 2

Their studies: Boehringer Ingelheim’s studies of Colitis, Ulcerative in search

Idiopathic Pulmonary Fibrosisboth · compare here

AbbVie in Idiopathic Pulmonary Fibrosis: 1 program

  1. ABBV-142phase 2

Their studies: AbbVie’s studies of Idiopathic Pulmonary Fibrosis in search

Boehringer Ingelheim in Idiopathic Pulmonary Fibrosis: 4 programs

  1. nerandomilastphase 3
  2. BI 3810477phase 2
  3. BI 765423phase 2
  4. BI 1819479phase 2

Their studies: Boehringer Ingelheim’s studies of Idiopathic Pulmonary Fibrosis in search

Breast Neoplasmsboth · compare here

AbbVie in Breast Neoplasms: 2 programs

  1. trifluridine tipiracil drug combinationphase 3
  2. RC148no phase

Their studies: AbbVie’s studies of Breast Neoplasms in search

Boehringer Ingelheim in Breast Neoplasms: 2 programs

  1. zongertinibphase 3
  2. pumitamigphase 2

Their studies: Boehringer Ingelheim’s studies of Breast Neoplasms in search

Geographic Atrophyboth · compare here

AbbVie in Geographic Atrophy: 2 programs

  1. ABBV-6628phase 2
  2. pegcetacoplanphase 2

Their studies: AbbVie’s studies of Geographic Atrophy in search

Boehringer Ingelheim in Geographic Atrophy: 2 programs

  1. BI 1584862phase 2
  2. BI 771716phase 2

Their studies: Boehringer Ingelheim’s studies of Geographic Atrophy in search

Neoplasmsboth · compare here

Boehringer Ingelheim in Neoplasms: 1 program

  1. ezabenlimabphase 3

Their studies: Boehringer Ingelheim’s studies of Neoplasms in search

Squamous Cell Carcinoma of Head and Neckboth · compare here

AbbVie in Squamous Cell Carcinoma of Head and Neck: 2 programs

  1. telisotuzumab adizutecanphase 3
  2. ABBV-711phase 1

Their studies: AbbVie’s studies of Squamous Cell Carcinoma of Head and Neck in search

Boehringer Ingelheim in Squamous Cell Carcinoma of Head and Neck: 2 programs

  1. ezabenlimabphase 3
  2. Anti-SIRPa Monoclonal Antibody BI 770371phase 2

Their studies: Boehringer Ingelheim’s studies of Squamous Cell Carcinoma of Head and Neck in search

Depressive Disorder, Majorboth · compare here

AbbVie in Depressive Disorder, Major: 2 programs

  1. icalcaprantphase 2
  2. bretisilocinphase 2

Their studies: AbbVie’s studies of Depressive Disorder, Major in search

Boehringer Ingelheim in Depressive Disorder, Major: 1 program

  1. Pramipexoleapproved, new study

Their studies: Boehringer Ingelheim’s studies of Depressive Disorder, Major in search

Obesityboth · compare here

AbbVie in Obesity: 1 program

  1. ABBV-295phase 2

Their studies: AbbVie’s studies of Obesity in search

Boehringer Ingelheim in Obesity: 2 programs

  1. survodutidephase 3
  2. BI 3034701phase 2

Their studies: Boehringer Ingelheim’s studies of Obesity in search

Ovarian Neoplasmsboth · compare here

Boehringer Ingelheim in Ovarian Neoplasms: 1 program

  1. Etoposidephase 3

Their studies: Boehringer Ingelheim’s studies of Ovarian Neoplasms in search

Renal Insufficiencyboth · compare here

AbbVie in Renal Insufficiency: 2 programs

  1. tavapadonphase 3
  2. emraclidinephase 2

Their studies: AbbVie’s studies of Renal Insufficiency in search

Boehringer Ingelheim in Renal Insufficiency: 1 program

  1. survodutidephase 3

Their studies: Boehringer Ingelheim’s studies of Renal Insufficiency in search

Carcinoma, Hepatocellularboth · compare here

AbbVie in Carcinoma, Hepatocellular: 1 program

  1. telisotuzumab adizutecanphase 3

Their studies: AbbVie’s studies of Carcinoma, Hepatocellular in search

Boehringer Ingelheim in Carcinoma, Hepatocellular: 1 program

  1. pumitamigphase 2

Their studies: Boehringer Ingelheim’s studies of Carcinoma, Hepatocellular in search

Diabetic Retinopathyboth · compare here

AbbVie in Diabetic Retinopathy: 1 program

  1. surabgene lomparvovecphase 3

Their studies: AbbVie’s studies of Diabetic Retinopathy in search

Boehringer Ingelheim in Diabetic Retinopathy: 1 program

  1. BI 764524phase 2

Their studies: Boehringer Ingelheim’s studies of Diabetic Retinopathy in search

Endometrial Neoplasmsboth · compare here

AbbVie in Endometrial Neoplasms: 1 program

  1. opugotamig olatansinephase 2

Their studies: AbbVie’s studies of Endometrial Neoplasms in search

Boehringer Ingelheim in Endometrial Neoplasms: 1 program

  1. BI 3820768phase 1

Their studies: Boehringer Ingelheim’s studies of Endometrial Neoplasms in search

Lupus Erythematosus, Systemicboth · compare here

AbbVie in Lupus Erythematosus, Systemic: 1 program

  1. ABBV-519phase 1

Their studies: AbbVie’s studies of Lupus Erythematosus, Systemic in search

Boehringer Ingelheim in Lupus Erythematosus, Systemic: 1 program

  1. BI 3000202phase 2

Their studies: Boehringer Ingelheim’s studies of Lupus Erythematosus, Systemic in search

Lymphoma, Large B-Cell, Diffuseboth · compare here

Boehringer Ingelheim in Lymphoma, Large B-Cell, Diffuse: 1 program

  1. Etoposidephase 3

Their studies: Boehringer Ingelheim’s studies of Lymphoma, Large B-Cell, Diffuse in search

Melanomaboth · compare here

AbbVie in Melanoma: 1 program

  1. vedolizumabphase 3

Their studies: AbbVie’s studies of Melanoma in search

Boehringer Ingelheim in Melanoma: 1 program

  1. BI 3810944phase 1

Their studies: Boehringer Ingelheim’s studies of Melanoma in search

Parkinson Diseaseboth · compare here

AbbVie in Parkinson Disease: 1 program

  1. tavapadonphase 3

Their studies: AbbVie’s studies of Parkinson Disease in search

Boehringer Ingelheim in Parkinson Disease: 1 program

  1. Pramipexoleapproved, new study

Their studies: Boehringer Ingelheim’s studies of Parkinson Disease in search

Scleroderma, Systemicboth · compare here

AbbVie in Scleroderma, Systemic: 1 program

  1. ABBV-722phase 3

Their studies: AbbVie’s studies of Scleroderma, Systemic in search

Boehringer Ingelheim in Scleroderma, Systemic: 1 program

  1. nerandomilastphase 3

Their studies: Boehringer Ingelheim’s studies of Scleroderma, Systemic in search

Strokeboth · compare here

AbbVie in Stroke: 1 program

  1. botulinum toxin type Aapproved, new study

Their studies: AbbVie’s studies of Stroke in search

Boehringer Ingelheim in Stroke: 1 program

  1. Tenecteplaseapproved, new study

Their studies: Boehringer Ingelheim’s studies of Stroke in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

A target, or a pathogen for a vaccine, known for: AbbVie 54 of 70 · Boehringer Ingelheim 24 of 45 programs (22 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (AbbVie: 8, Boehringer Ingelheim: 21).